Current first-line treatment for metastatic gastric cancer includes targeted therapy, particularly for HER2-positive cases, and immunotherapy for PD-L1-positive disease, both of which have been shown to improve median OS to 13–14 months [15,16,17,52]. The gene discussed is ERBB2; the disease is gastric cancer.